Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Continued Examination Under 37 CFR 1.114
A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 12/22/2025 has been entered.
Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objects are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application.
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claims 1-9, 11-16, and 20-25 are rejected under 35 U.S.C. 103 as being unpatentable over WO 2006/126095 to Hitz (IDS filed 1/26/2021) in view of WO 2017/055536 to Geraths (IDS filed 1/27/2021). Hitz teaches a copolymer containing multiple molecules of an active agent, comprising polymerization of a reaction mixture comprising (1) one or more polymerizable principal monomers, which monomers are characterized as having at least one vinylic group and not containing an amino acid residue, such as 2-phenylethylacrylate, 2-phenylethylmethacrylate and butanedioldiacrylate (example 20), and 2-hydroxyethylmethacrylate, and ethylene glycol diacrylate (example 21)); one or more co-principal monomers of formula I or II in which at least one of Y and Z is H (examples 20 and 21); an initiator system for generating free radical species such as di-(tert-butylcyclohexyl)peroxydicarbonate and azobisisobutyronitrile) (examples 20-21), the polymerization yielding a copolymer, coupling of the active agent to the copolymer after polymerization of the reaction mixture (abstract; page 2, first full paragraph to page 7, first full paragraph; Examples 20-22). This is a copolymer containing multiple molecules of an active agent made by polymerization of a reaction mixture comprising one or more polymerizable principal monomers, which monomers are characterized as having at least one vinylic group and not containing an amino acid residue, one or more co-principal monomers corresponding to applicant’s formulae I or II in which at least one of Y and Z is H, an initiator system for generating free radical species, the polymerization yielding a copolymer; and coupling of the active agent to the copolymer after polymerization of the reaction mixture. The active agents may be hydrophobic steroids, triamcinolone, anecortave acetate, and dexamethasone loaded onto (coupled to) the polymer (dexamethasone is used to treat cancer; an intercalating drug; an anti-inflammatory substance) (Examples 20-22).
Hitz fails to teach an agent for controlling radical polymerization. Hitz further fails to teach covalent bonding of the active agent.
Geraths teaches a copolymer made by polymerization of a reaction mixture (a polymerization mixture), comprising one or more polymerizable principal monomers, which monomers are characterized as having at least one vinylic group and not containing an amino acid residue, one or more co-principal monomers of formulae I or II in which at least one of Y and Z is H (step (b) and (c), an agent for controlling radical polymerization (chain transfer agent), and an initiator system for generating free radical species (free radical initiator), the polymerization yielding a copolymer (abstract; page 1, first paragraph; page 4, bottom paragraph to page 9, second full paragraph; claim 1) and is therefore in the same field of invention as Hitz. Geraths teaches that incorporation of an agent for controlling radical polymerization desirably produces less polydispersity and a narrower size distribution (pages 16-17, bridging paragraph). Geraths teaches a copolymer containing multiple molecules of an active agent made by polymerization of a reaction mixture (a polymerization mixture), comprising one or more polymerizable principal monomers, said monomers are characterized as having at least one vinylic group and not containing an amino acid residue, one or more co-principal monomers of formulae I or II in which at least one of Y and Z is H (steps (b) and (c)), an agent for controlling radical polymerization (chain transfer agent),and an initiator system for generating free radical species (free radical initiator), the polymerization yielding a copolymer (abstract; page 1, first paragraph; page 4, bottom paragraph to page 9, second full paragraph; claim 1). Geraths teaches use of functionalized co-principal monomers of formula I, formula II, or a combination (Example 17), wherein the hydrophobic side chain linked amino acids of formula I or formula II have their alpha-amino and/or carboxyl groups functionalized with alkyl or cholesteryl residues and other hydrophobic monomers (pages 30-31, bridging paragraph). The functionalized alkyl or cholesteryl residues and other hydrophobic monomers are taught to have high capacity for binding water molecules and enhanced surface wettability and lubricity. This is a copolymer containing multiple molecules of an active agent made by polymerization of a reaction mixture comprising one or more polymerizable principal monomers, which monomers are characterized as having at least one vinylic group and not containing an amino acid residue, one or more co-principal monomers corresponding to applicant’s formulae I or II in which at least one of Y and Z is H, an agent for controlling radical polymerization and an initiator system for generating free radical species, the polymerization yielding a copolymer; and coupling of the active agent to the copolymer after polymerization of the reaction mixture. Geraths teaches an average molecular weight of the copolymer of 5,000 to 100, 000 Daltons for at least 80% of the copolymer (pages 8-9, bridging paragraph; claim 3). The agent for controlling radical polymerization (chain transfer agent) is a RAFT agent (pages 16-17, bridging paragraph; Examples 14 and 17; claims 4 and 13). Geraths teaches two success polyermization reactions for the copolymer, wherein the first polymerization reaction is carried out in a first reaction mixture comprising one or more polymerizable principal monomers not containing an amino acid group, a RAFT agent for controlling the copolymerization, and an initiator system for generating free radical species, the polymerization yielding a RAFT pre-polymer (Step A, page 31), and wherein the second polymerization reaction is carried out in a second reaction mixture comprising the RAFT pre-polymer of the first polymerization reaction, one or more co-principle monomers of formulae I and/ or II, and an initiator system for generating free radical species (Step B, page 32), wherein the RAFT agent may be used in Example 17 is 2-(dodecylthiocarbonothioylthio)-2- methylpropionic acid(Example 17) which comprises a monodisperse spacer of 5-25 units, a carboxyl group (comprising a carboxyl group) which may be used for functionalization of the copolymer with a cell type-specific or a tissue type-specific targeting moiety (claims 7-8 and 14-15).
It would have been obvious to one of ordinary skill in the art at the time the invention was made to use an agent for controlling radical polymerization in the method of making of Hitz. The motivation for this would be to control radical polymerization in the preparation of the polymer to provide a narrow size distribution and smaller polydispersity. A smaller polydispersity in the polymer network would aid in providing a uniform distribution of the active agent, as desired by Hitz (pages 18-19, bridging paragraph). Regarding claim 24, which recites the copolymer of claim 1, “wherein the tracer molecule is a fluorophore,” and claim 25, which recites the copolymer of claim 11, “wherein the tracer molecule is a fluorophore,” these claims limit the member of the Markush group in the base claims wherein the active agent is a tracer molecule, but do not positively recite that the tracer molecule is a fluorophore. As the art currently applied reads on that embodiment of the Markush group in the independent claims wherein the active agent is cytotoxic agent or an anti-inflammatory substance, it is deemed to also read on claims 24-25, which limit the tracer molecule in the Markush group of claims 1 and 11, but do not positively recite that the tracer molecule is present. It would have been further obvious to try covalent bonding as the means of connecting the active agent to the carrier. The motivation for this would be to ensure the active agent stayed attached to the carrier until it was administered. It would be well within the purview of the artisan to decide between the limited choices of covalent and non-covalent bonding.
Applicant’s arguments have been fully considered but are not found persuasive. Regarding applicant’s argument that the claims require that the active agent be covalently attached to the copolymer, the examiner’s response is that the claims nowhere recite “covalent” nor language that limits the invention to covalent bonding. What is claimed is coupling of the active agent to the copolymer. Although chemical coupling may include covalent bonds, it also includes ionic bonds, hydrogen bonds, and other non-covalent attaching means. In the present case, the active agent is coupled to the copolymer for the reasons set forth above. Regarding applicant’s arguments regarding Hitz and Geraths in isolation, the examiner’s’ response is that the rejection is not based on Hitz and Geraths alone, but on what the combination of Hitz and Geraths would motivate the artisan to do. Regarding applicant’s that the polymers of Hitz comprise a non-functionalized amino acid moiety which are excluded from the invention, the examiner’s response is that the present claims use the term “comprising” to describe the components of the reaction mixture, and the reaction mixture is therefore open to monomers not enumerated in the claim, including monomers comprising non-functionalized amino acids. Regarding applicant’s argument that dexamethasone is not an anti-cancer agent, the examiner’s response is that is an agent used to treat cancer, and is therefore fairly an anti-cancer agent. For support, the examiner cites UPMC Hillman Cancer Center’s publication regarding dexamethasone which states “Dexamethasone is used to treat cancer” (https://hillman.upmc.com/patients/community-support/education/chemotherapy-drugs/dexamethasone#:~:text=Dexamethasone%20is%20used%20to%20treat,sheet%20about%20Dexamethasone%20(PDF), accessed 3/18/2025; document already in record). Even if dexamethasone were not used to treat cancer, it is an anti-inflammatory agent, which reads on “anti-inflammatory substance.” Regarding applicant’s argument that Hitz does not teach and there would be no motivation for active agents to be covalently attached to the polymer, the examiner’s response is that Hitz teaches a copolymer containing multiple molecules of an active agent, comprising polymerization of a reaction mixture comprising (1) one or more polymerizable principal monomers, which monomers are characterized as having at least one vinylic group and not containing an amino acid residue, such as 2-phenylethylacrylate, 2-phenylethylmethacrylate and butanedioldiacrylate (example 20), and 2-hydroxyethylmethacrylate, and ethylene glycol diacrylate (example 21)); one or more co-principal monomers of formula I or II in which at least one of Y and Z is H (examples 20 and 21); an initiator system for generating free radical species such as di-(tert-butylcyclohexyl) peroxydicarbonate and azobisisobutyronitrile) (examples 20-21), the polymerization yielding a copolymer, coupling of the active agent to the copolymer after polymerization of the reaction mixture (abstract; page 2, first full paragraph to page 7, first full paragraph; Examples 20-22). This is a copolymer containing multiple molecules of an active agent made by polymerization of a reaction mixture comprising one or more polymerizable principal monomers, which monomers are characterized as having at least one vinylic group and not containing an amino acid residue, one or more co-principal monomers corresponding to applicant’s formulae I or II in which at least one of Y and Z is H, an initiator system for generating free radical species, the polymerization yielding a copolymer; and coupling of the active agent to the copolymer after polymerization of the reaction mixture. Although Hitz fails to teach an agent for controlling radical polymerization, it would have been obvious to use an agent for controlling radical polymerization in the method of making of Hitz. The motivation for this would be to control radical polymerization in the preparation of the polymer to provide a narrow size distribution and smaller polydispersity. A smaller polydispersity in the polymer network would aid in providing a uniform distribution of the active agent, as desired by Hitz (pages 18-19, bridging paragraph). Regarding applicant’s that the claims do not anticipate covalent bonding of the active agent, the examiner’s response is that it would have been further obvious to try covalent bonding as the means of connecting the active agent to the carrier. The motivation for this would be to ensure the active agent stayed attached to the carrier until it was administered. It would be well within the purview of the artisan to decide between the limited choices of covalent and non-covalent bonding.
Claims 1-17 and 20-25 are rejected under 35 U.S.C. 103 as being unpatentable over WO 2017/055536 to Hitz in view of Geraths in further view of Willcock (Polym. Chem., 2010). The relevant portions of Geraths are given above.
Hitz and Geraths fail to teach wherein the RAFT group of the RAFT agent is eliminated subsequent to polymerization or functionalization of the polymer.
Willcock teaches that failure to remove the RAFT group functionality of RAFT agents subsequent to polymerization or functionalization of polymers prepared by RAFT polymerization leaves residual RAFT agent functionality within the polymer which poses a problem due to the agent’s inherent reactivity and decomposition into sulfur-containing materials) (page 150, right column, first full paragraph). Accordingly, the RAFT group is conventionally removed (eliminated) to avoid such complications by several methods known in the art (page 150, right column, second full paragraph to page 151, left column, second full paragraph).
It would have been obvious to one of ordinary skill in the art at the time the invention was filed to eliminate the RAFT group of the RAFT agent subsequent to polymerization or functionalization of the polymer. The motivation for this is to avoid residual activity of the RAFT group within the polymer which poses problems due to the agent’s inherent reactivity and decomposition into sulfur-containing materials.
Applicant’s arguments have been fully considered but are not found persuasive. Regarding applicant’s arguments in relation to Hitz and Geraths, these were addressed above. Willocck was relied on for its teaching that failure to remove the RAFT group functionality of RAFT agents subsequent to polymerization or functionalization of polymers prepared by RAFT polymerization leaves residual RAFT agent functionality within the polymer which poses a problem due to the agent’s inherent reactivity and decomposition into sulfur-containing materials) (page 150, right column, first full paragraph). Accordingly, the RAFT group is conventionally removed (eliminated) to avoid such complications by several methods known in the art (page 150, right column, second full paragraph to page 151, left column, second full paragraph). It would have been obvious to eliminate the RAFT group of the RAFT agent subsequent to polymerization or functionalization of the polymer. The motivation for this is to avoid residual activity of the RAFT group within the polymer which poses problems due to the agent’s inherent reactivity and decomposition into sulfur-containing materials.
Conclusion
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to PAUL W DICKINSON whose telephone number is (571)270-3499. The examiner can normally be reached on M-F 9 AM to 7:30 PM.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Hartley can be reached on 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/PAUL W DICKINSON/Primary Examiner, Art Unit 1618
January 10, 2026